Adlai Nortye (ANL) Equity Average (2023 - 2024)
Adlai Nortye (ANL) reported Equity Average of $39.4 million for Q4 2024, up 147.43% year-over-year from $15.9 million in Q1 2024, and down 38.59% on a QoQ basis from $64.2 million in Q2 2024.
Adlai Nortye (ANL) has 2 years of Equity Average data on file, last reported at $39.4 million in Q4 2024.
- Quarterly Equity Average rose 147.43% year-over-year to $39.4 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $39.4 million (up 147.43% YoY) and the FY2025 annual result came in at $8.6 million, down 82.93% from the prior year.
- Equity Average eased to $39.4 million in Q4 2024 per ANL's latest filing, from $64.2 million in the prior quarter.
- Across five years, Equity Average topped out at $64.2 million in Q2 2024 and bottomed at -$83.1 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | 3.76 Mn |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | 21.35 Mn |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 19.01 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 31.34 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 932.28 Mn |
| 10 | Adlai Nortye | 23,840.00 | -8.03 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 39.43 Mn |
| Jun 30, 2024 | 64.21 Mn |
| Dec 31, 2023 | -83.12 Mn |